impact medicine feel well live long corporate social responsibility report corporate responsibility integral business inherent mission company glaxosmithkline make significant positive contribution society world medicine healthcare product research develop manufacture sell content global challenge value people scope business environment health safety contribution society business ethic integrity medicine develop world management csr community investment web reference research development impact medicine cover story generation separate bettina bartel son philippe able lead active life despite suffer asthma story find annual review report vincent mcgovern give perspective asthma management patient doctor annual report annual review corporate social responsibility reportdure invest total million global community activity product donation charitable contribution company donate million albendazole tablet worth million country support prevention lymphatic filariasis increase shipment combivirhivaid treatment preferential price develop world nearly million tablet million work companiesto establish new industry principle conduct clinical trial communication clinical trial result survey manager view gsk spiritand culture global challenge responsible behaviour type product improve people live ensure organisation include multinational profitable sustainable future business company government charity high understand public agenda stimulate considerable profit matter stakeholder include debate year review corporate employee want know profit social responsibility cover gsk reassure sound ethical basis year new company set business commitment connect business decision ethical social environmental concern run business effectively talking listen group report cover activity business impact discussion stakeholder cover issue generate significant everyday work interest stakeholder good way relationship view expectation progress year include develop indicator stakeholder directly affect enable progress address issue continue build consult widely formally formal step increase transparency way diversity stakeholder example operation way expect patient customer healthcare professional stakeholder confidence value government nongovernmental organisation business feel shareholder inevitably give rise different conflict demand consider corporate responsibility integral continue constructive engagement business inherent mission guide run successful business company gsk make significant positive contribute meeting need society contribution society world medicine vaccine healthcare product research develop manufacture sell sir christopher hogg garni chairman chief executive officer glaxosmithkline research develop manufacture market medicine consumer health product world scope business employee operating country research development centre country production facility country key impact area disease medicine community ethical issue develop world develop world investment continue commitment facilitate access improve quality consider question find prevention medicine improve life underserve people arise research treatment particularly health education develop development new hivaids malaria partnership develop world medicine vaccine glaxosmithkline scope business glaxosmithkline operate pharmaceutical commercialise support effective marketing consumer healthcare sector make prescription prescription medicine vaccine delivery system medicine vaccine overthecounter medicine treatment prevention human disease oral care nutritional healthcare product employ staff site worldwide business found primarily research development discover develop register portfolio product range tablet toothpaste inhaler capsule different pack size presentation financial profile network manufacturing site country employ sale manufacture relate support function trading profit year produce billion pack businessperformance deliver sale country spend pharmaceutical industry highly regulate sale stage discovery sale marketing closely control stakeholder usa pharmaceutical expectation different europe pharmaceutical international pharmaceutical size complexity challenging consumer healthcare business raise question information financial performance available main impact annual report account society manage describe report developingour support care business employee human right environment ethic attract rewarding respecting right resource efficiently ensure employee motivate people safe interest minimise negative understand implement healthy workplace affect involved environmental impact code conduct business policy ensure ethical business practice contribution society main activity company develop country availability effective antibiotic vaccine long develop medicine include vaccine expect child risk infectious valuable contribution disease challenge extend advance develop country society medicine save live number disease research relieve suffering treat produce major advance continue grow prevent disease improve quality challenge company continue meet societys life patient carer expectation develop innovative medicine enable people live long healthy life enable people carry life reduce cost access medicine want play improve manage illness healthcare people currently limit access medicine programme develop country set positive effect medicine helping improve access people live factor medicine lowincome senior citizen motivate employee nature disabled lack prescription drug coverage give opportunity public private insurance programme difference health million people late gsk launch orange cardsm world offer saving company prescription medicine programme change expectation kind participant require simply advance medicine society change present card pharmacist receive expectation healthcare disease saving addition year gsk patient devastating impact control assistance program provide medicine worth improve healthcare management million low well medicine vaccine lead income patient people develop world good medical insurance health grant follow positive response orange card example generation ago polio patient doctor company gsk world fear infectious disease thanks pharmaceutical company launch joint worldwide vaccination initiative coordinate scheme cardprovide world health organizationand major eligible senior citizen disable contribution vaccine business global single easytouse card receive saving elimination polio sight prescription medicine seven company involve gsk open door programme real impact significant saving estimate life disadvantage people million americans tremendous difference live people tommy thompsonus secretary health human service launch orange card case study asthmarelate death hospital admission decline incidence asthma grow asthma remain major health issue worldwide focus matter patient concentrate quality life development vincent mcgovern general doctor perspective asthmatreatment practitioner belfast give asthmatic find asthma satisfy condition perspective asthma management treat common million sufferer fsventolinbronchodilator patient doctor practice cent relieve breathlessness hour dose asthmatic mildtomoderate disease aim patient perspective management achieve total control symptom fsbecotidebeclovent corticosteroid reduce asthma change dramatically current treatment give good quality inflammation lung year child want play football life standard patient care getting lead asthma symptom play goal rounded shoulder higher specialise unit oneto fssereventbronchodilator blue inhaler pocket remember consultation nurse doctor asthma relieve breathlessness hour dose sleepless night emergency visit area national treatment guideline doctor inhale steroid available adopt major impact fsflixotideflovent corticosteroid effectively take away sleepless night development disease management reduce inflammation new treatment huge impact lung lead asthma symptom life asthma control year organisation preventative treatment certainly notice produce improve medicine treat asthma ftodayseretideadvair bronchodilatorcorticosteroid well way take advance asthma product vital enable healthcare professional relieve breathlessness hour dose reduce provide everimprove patient care inflammation lead asthma cause suffer death asthma symptom easy use device continue research aim improve life grow number people affect disease develop country million people lack access basic healthcare service lifethreatening disease tuberculosis malaria hivaid contribute healthcare crisis medicine develop world global community provide political significant mobilisation additional resource spirit partnership improvement healthcare quality life develop world glaxosmithkline make vital contribution ddw development pipeline end healthcare develop country preclinical action area invest research activity phase phase phpahsae siiei iii market development target disease vaccine hiv hepatitis psn epunmeuomnioaneiae havrix hepatitis particularly affect develop world dengue fever rotavirus paepdaieadtriiactric engerix hepatitis meningitis twinrix hep preferential pricing antiretroviral malaria infanrix diptheria tetanus meningitidi acellular pertussis antimalarial vaccine community tritanrix diptheria tetanus wholecell pertussis investment activity partnership polio sabin polio priorix measle mump foster effective healthcare rubella typherix typhoid significant advance key hiberix haemophilus influenzae type area hiv nnrti integrase inhibitor ziagzeiangeepniveipr ivir retrovir protease inhibitor comcobminbaitnioantion epivir combivir disease develop world ziagen trizivir research disease develop world agenerase protease inhibitor ddw particularly important address unmet need minimise intrinsic threat malaria cda tafetanfoeqnuoiqnueine malarone halfan infectious disease resistance develop lapdap exist treatment sitamaquine oxibendazole sitasmitaamquaiqnueine zentel dedicated ddw group create oxiboexinbdeanzdoalezole gsk organisation ensure focus register market area project prioritise primarily socioeconomic public health benefit disease primarily affect develop commercial return ddw research world malaria differ important respect focus dedicated facility tre canto effort aim disease develop spain world market exist hivaids lack commercially viable market ddw treatment believe gsk industry extensive mean publicprivate partnership essential portfolio ddw project market major company gsk provide product company technological development manufacturing undertake prevention treatment distribution expertise public sector partner world health organization help fund development cost ensure priority disease develop world hivaid new medicine vaccine people tuberculosis malaria gsk focus need partnership approach encourage disease industry leader accelerate product uptake collaborate external partner want develop world use specialist infrastructure expertise longterm commitment number supply arrangement arvs type ofcustomer bear fruit hopeful able launch new product relevant ddw year key employer ngo aaiaccelerate access public hospital govt non aai initiative maintain broadly current level human lapdapresult successful partnership financial resource dedicate ddw gsk world health organization proportion total investment university liverpool london school work assiduously partner appropriate hygiene tropical medicine ensure promise ddw drug department international development dfid available patient rapidly possible product development process lengthy risky long directly sponsor dfid term commitment bear fruit hopeful able launch new preferentialpricing product relevant ddw year gsk recognise responsibility product affordable possible poorest see notable progress country offer vaccine public hivaid human clinical trial health programme significant discount hiv candidate vaccine commence february year set single sustainable notforprofit collaboration government national preferential price antiretroviral institutes health hiv vaccine trial network arvs antimalarial wide range conjunction partner gsk continue customer develop country support hiv clinical trial develop country subsaharan africa total country include africa purpose trial customer include public sector notforprofit assess use antiretroviral therapy treatment ngo aid agency agencies international prevention mothertochild hiv transmission purchase fund global fund fight resourcepoor setting patient form aid malaria extend offer form hiv collaborative study notforprofit price arvs employer thousand patient include subsaharan africa provide care treatment dart trial develop antiretroviral therapy workplace clinic similar arrangement uganda zimbabwe coordinate special access pack medical research council gsk commit contribute health improvement sustainable manner set progress malaria october preferential price arvs antimalarial submit regulatory application level cover direct cost medicines control agency mca lapdap profit way offer chlorproguanildapsone treatment price long patient need treatment life threaten type malaria mca approval important step make lapdap available africa great need new malaria treatment stnemegnarra ylppuscumulative shipment combivir tablet exclude divert product pledge pass cost efficiency additionally start smallscale shipment develop world increase shipment wide range preferentiallyprice instance september reduce product pilot project notforprofit preferential price hivaid partnership ngo tanzania uganda nigeria medicine cent antimalarial zambia malawi project design medicine cent assess impact preferential pricing broad range product end secure arrangement supply preferentiallypriced arvs community investment programme country include arrangement wide range partnership arrangement wide develop world focus health range stakeholder include government education programme underserve community ngos public hospital employer world gsk invest heineken anglo american million public health programme commence partnership partner range world health result increase shipment combivir organization world bank local school develop world million tablet communitybase organisation possible nearly million tablet ensure programme sustainable equivalent million daily dose repeat community similar need figure exclude product destine patient africa divert europe programme comprise major initiative public victim trade hivaid patients africa health support education product donation beneficiarie illegal importer support employee involvement activity gsk introduce special access pack public health programme example include illegal trade difficult look regulatory authority customer measure global alliance eliminate lymphatic prevent diversion filariasis gsk key partner global effort eliminate lymphatic filariasis know gsk ability provide preferential price elephantiasis disable disfigure develop world require sustainable framework disease currently affect million people commitment preferential pricing threaten billion combine commitment prevent poor nation world product diversion avoid reference develop country price preferentiallyprice medicine clearly diversion threatens framework snoillim deppihs stelbatour partner range world health organization world bank local school communitybase organisation gsk found member partnership positive action programme gsk include world health organization ministry international programme hiv education care health lfendemic country community support back international organisation public private academic programme country activity fund sector gsk donate antiparasitic drug albendazole positive action support twoyear live let drug stop transmission live world aids campaign launch unaid disease anticipate year life world aids day example positive action programme commitment build fund study international center estimate billion tablet country join research woman conduct ethiopia addition provide significant financial resource tanzania zambia confirm societal staff expertise support coalitionbuilde discrimination base hiv fuel spread advocacy research community mobilisation aid positive action announce fund educational initiative new community initiative kenya mexico international aids conference fourth year programme million hold barcelona july positive action tablet worth million donate contribute support attendance country bring total number albendazole participation community representative tablet donate date million grant total underresourced region huge mobilisation effort require fight gskfrance foundation support exemplified health worker programme prevent risk vertical volunteer sri lanka work transmission hiv provide medical care deliver preventative medicine million people monitor treatment improve access single day july quality care people live hiv foundation support programme involve people year million commitment african country african malaria partnership amp november organisation select share grant total million year amp programme gsk fund behavioural development initiative combat disease kill million people year total nearly million people reach programme seven country involve snoillim glaxosmithkline proud improve healthcare develop world drug distribution research development community activity world attention focus private company government work constance carrinodirector office hivaid usaid elimination programme million albendazole tablet donate date year key estimate patient treat tablet donate mcase study gsk research disease develop world ddw centre dedicated facility tre canto spain addition hivaid vaccine programme gsk tre canto site house major element tre canto group fully integrate highthroughput screening activity rest gsk order ensure gsk commercial operation spain bring relevant skill technology concentrate resource bear achieve success develop ddw drug research malaria effort discovery regard gsk advantage long history gsk dedicated scale network key external facility site fulltime research partner important staff commit solely ddw particular access gsk worldwide clinical centre malaria focus idea development organisation vital effective drug candidate treat neglect conduct clinical trial ddw group disease develop world pursue tre canto associate ddw drug opportunistically development exist development team london gsk drug candidate disease continue gsk expertise staff area screen preclinical development tre cantos ddw scientific staff provide regulatory affair wide range skill include chemistry biology toxicology need well understand disease target identify novel drug candidate development concentration resource skill maximise ability discover new medicine ddw total value community investment activity million project hopeairlift gsk antibiotic tajikistan product donation humanitarian relief reach country community investment focus glaxosmithkline community investment improve health education programme extend developed develop world effort target improve quality life people underserve community work partner organisation decade steady immigration refugee world ensure right blend afghanistan member partnership expertise apply programme quality medical donation gsk fully endorse select partner well agree follow guideline experience skill initiative drug donation programme select basis community need potential impact public health programme direct gsk commercial business increase area specific disease prevalent sale product fund programme mean hivaids community programme measurable sustainable replicable positive action global reach effort work closely partner ensure eliminate parasitic disease lymphatic filariasis success focus endemic country develop world african malaria partnership worldwide community contribution direct continent bear great gsk community investment charitable burden disease contribution total million million relate company patient develop world community assistance program financially disadvantaged programme support community need patient corporate regional public share programme canada health humanitarian relief programme aim target health elderly racial ethnic minority serve community great need meet community provide monetary award local need gsk operating company support innovation share good practice reduce numerous local community programme health inequality vulnerable group gsk product donation humanitarian relief charitable partner organisation experience deliver humanitarian relief fund programme charity decide product measurable sustainable donation need work government recipient country ensure replicable work arrive safely distribute appropriately example donation half million closely partner treatment antibiotic augmentinwa ensure success airlift vital medicine tajikistan october organised project hope struggle overcome effect civil war tajikistan challenge international business leader forum award international corporate citizenship gsk phase programme provide hygiene education school child charity plan impress gsk approach partnership willing consult local community develop material easy use relevant local culture save children live marie stauntonexecutive director plan international phase programme make real difference health wellbee local community excellent example positive role business society robert davieschief executive international business leader forum method giving include uspatient assistance program broad commitment science type programme education commit million exclude uspatient assistance program year fund inspire innovative scheme public health programme include postdocs research education programme boost science education school product donation support select school apply corporate regional programme science college government specialist school programme local programme cash gsk provide support different way example donate money product inkind donation office furniture computer surplus laboratory equipment product donation value wholesale acquisition cost relate price gsk charge wholesaler warehouse chain retail price kind company follow london benchmarke groupmodel recording community investment recognise model provide standard basis company manage report commitment community product case study wide range seriously debilitate life threaten disease thrive poor living condition find country develop world africa million child die year diarrhoeal disease gsk launch initiative call phase container handwash pit latrine personal hygiene sanitation education refuse pit provide hygiene education school child aim reduce diarrhoea evaluation kenyan programme show relate disease death associate result phase child well poor hygiene understanding cause diarrhoea worm infestation know way phase start partnership amref african prevent infection teacher see improvement medical research foundation operate school attendance report child kenya nicaragua peru gsk cleaner well care commit million rollout latin personal hygiene datum class america gsk work childfocused percentage child know wash development charity plan international kenya hand go toilet prevent worms children school benefit increase cent phase basic education nicaragua cent reach primary school child peru success programme kenyan government incorporate phase phase empower child family national curriculum increase responsibility health likelihood benefit available sanitation community participate part kenya school benefit home understand need balance benefit patient gain new medicine risk ethical consideration relate new technology research development glaxosmithkline aim produce safe effective medicine vaccine benefit patient address unmet medical need need use recent advance science technology understand disease identify test drug unable advantage encourage staff devise alternative approach advance patient good animal research internal animal welfare animal research treatment understand concern awards gsk sponsor large european award technological advance process field gsk laboratory animal welfare welcome inform debate prize inspection national regulatory authority acknowledge high standard care reduce process highly regulate compliance facility ensure operate scientific advance raise new issue meet good practice animal facility work closely regulator policy maker accredit association assessment stakeholder develop new refined accreditation laboratory animal care standard internal standard work extend facility system ensure comply exceed refine guideline regulation legal requirement believe good way address public interest animal research foster great essential role animal research knowledge understanding fact basic research animal vital furthering believe effective way understand human disease animal help combat climate fear intimidation study provide essential bridge promote animal extremist group replace characterise potential new medicine vaccine provide information support rational laboratory learning effect public debate actively participate discussion people law assess drug safety host tour animal facility animal start clinical trial possible welcome government commit reduce refine action protect staff laboratory animal reducethe number animal medicine replace animal study set stringent standard research collaborator extremist action minimum possible obtain internally external contractor visit school discuss relevant ethical issue meaningful validate result ensure gsk staff conduct animal study example involve pupil thoroughly train discussion school year refineanimal experimental procedure avoid minimise information gsk use animal research available pain discomfort reduce number animal research website maximise information compromise safety obtain study volunteer patient clinical trial animal oblige law seek information possible animal study number animal assess drug safety replacethe need animal study develop laboratory remained essentially validate alternative approach animal start constant year spite feasible significant increase activity chart clinical trial use animal humanely example noninvasive imaging rapid technological advance provide tool major progress fight disease test new medicine clinical trial principle reflect importance independent gsk aim develop medicine vaccine institutional review board ethical review benefit patient reflect priority committee protect patient volunteer protect interest healthy volunteer involve clinical trial gsk fully support patient clinical trial guideline reiterate need obtain regulatory authority rigorously scrutinise genuinely inform consent clinical initiation conduct clinical trial relate procedure undertake obligation gsk activity need respect right dignity extend include acquire human safety wellbee clinical trial participant biological sample tissue dna enshrine declaration guideline produce principle summarise safeguard world medical association world health industry include gsk adopt ensure organization council international reimbursement patient external clinical organisation medical sciences council investigator expense inappropriate europe international conference inducement participate clinical trial bias harmonisation ich government body result report regulatory authority gsk fully comply relevant regulation requirement financial disclosure protect national requirement guideline public interest area ich good clinical practice regulation guideline periodically review revise principle articulate industry gsk ensure fully address interest practice seek publish meaningful result patient gsk actively contribute discussion control clinical trial regardless outcome basis extensive global experience timely manner include give clinical trialist appropriate level access raw datum review summarise rigorous interpretation procedure ensure patient safety privacy medical information recently strengthen procedure avoid information send gsk external investigator enable identify trial participant know conduct clinical trial raise ethical issue work company establish new phrma principle conduct clinical trial communication clinical trial result ecni egnahc change activity compare change number animal gsk year figure normalise level key animal activitycase study noninvasive imaging technique magnetic resonance imaging mri provide new relevant scientific information way previously possible refining research animal serial mri allow respiratory biologist study lung study disease effect drug inflammation rat mimic aspect period time animal previously human asthma animal scan humanely kill organ minimise discomfort week allow removed microscopic examination chronic inflammatory response timepoint mri enable animal study beneficial effect standard repeatedly assess timepoint new drug measure mri approach number animal reduce typically require animal study require undertaken detailed information conventional microscopy approach progress disease frequent scanning possible timepoint similar approach take need separate group animal resource research area neurology psychiatry intensive technology microscopic cardiovascular disease preclinical examination importantly animal safety assessment cumulative beneficial impact control statistical power study enhance far number animal datum quality few animal significant gsk employ people operate country value people people great single source competitive advantage company glaxosmithkline believe attract retain motivating good people foundation future success commit provide opportunity survey result generally positive employee meaningful showing manager great pride challenge work pursuit goal gsk example overwhelming improve quality human life enable support statement people people feel well live long department commitment performance integrity department focus organisation year report principle underpin sense urgency gladly refer approach people management range good friend family member gsk programme design deliver global employment finding manager human resource strategy please believe gskspirit reflect way report progress set work day day able intend future measure performance issue diversity result raise important area development include concern gsk culture people able perform potential gsk great emphasis place extent manager able act coach achieve company support development degree staff deliver achievement culture sum involvement decision affect work gsk spirit define quality issue address gsk corporate expect employee embrace executive team example programme place reduce complexity bureaucracy performance integrity company streamline process help free entrepreneurial spirit manager good work focus innovation sense urgency passion achievement survey result develop gsk culture critical enable generally positive people reach potential good work carry survey show manager manager assess spirit great pride culture adopt seek view experience work gsk include gsk manager consider area need work fundamentally commit principle equality opportunity equal treatment diversity ethnicityofusemployeepopulation diversity business imperative gsk commit principle equality opportunity equal treatment aim workforce working environment reflect diversity background culture belief people characteristic community colour operate embed value diversity total employee equal treatment key business process employee mean diversity measure include manager employee training external human right recruitment internal appointment process gsk believe human right issue performance assessment pay review lead example influence succession plan developmental assignment behaviour practice clear demonstration value effective customer stakeholder include contribution pursue policy development measure reach target operation respect right customer outreach program specific interest affect involved patient group advertising reflect business gsksupport commit community serve uphold united nations universal declaration human rightsand core labour standard believe diversity strategy clear set international labour organization progress baseline figure report year report change annually carry internal review demonstrate operate employer believe comply global senior management population universal declaration human right gender man woman core convention international labour organization accord guideline band multinational enterprise set oecd band conduct head human resource band country review total build awareness understand human right issue corporate executive team vicepresidentssenior vice president director level manager level year begin place bind requirement ensure major exception ethnicity chart contractor supplier adopt gsk standard meaningful datum ethnicity human right core labour standard employee different way ethnic group describe different country case legal restriction collect data case study promotion diversity gsk powerful effect way think need customer ensure medicine benefit widest building success cultural awareness train possible number patient heart extend sale group mission enable people feel approach well live long gsk gsk pharma marketing department general pharma sale marketing unit increase multicultural awareness key business objective understanding relate brand improve access gsk medicine patient ethnic minority community addition multilanguage patient education programme support unit operate southern california healthcare professional raise awareness particularly high population vietnamese disease disease management group koreans armenians central americans limited command english disease education mexican material asthma migraine rhinitis depression provide gsk sale sale team specific training cultural representative number language include awareness improve understand spanish chinese vietnamese korean russian customer particular need result doctor well able use gsk product benefit individual patient community gsk comprehensive programme characterise physical chemical property environmental fate effect occupational health effect product chemical process environment health safety responsible global citizen glaxosmithkline strive preserve environment protect health people work comprehensive framework contractor site environmental health safety programme work direct supervision safety provide structure approach important employee apply base ehs standard apply standard monitor health exception site safety external contractor work gsk world lose time injury illness rate similar rate employee environmental sustainability basis environmental programme address improve ehs performance strong potential adverse impact waste ehs management system programme place approach achieve sustainability focus example give improve efficiency manufacturing process minimise material ehs information product process waste generate optimise use gsk comprehensive programme renewable raw material characterise physical chemical property environmental fate effect occupational occupational health safety programme health effect product chemical focus protect enhance health process information help safety employee reflect value place people fdesign operate production control system protect employee improvement target community operate ehs performance target set finform employee public baseline performance year hazard material help understand gsk operation achieve handle safely end environmental emission companywide target set gsk dry powder device consolidate individual site target health safety target reduce lose time injury illnesse cent year baseline rate lose time injury illnesse hour work preliminary datum indicate meet target year final verify result website wwwgskcom enilesab contract manufacturer decommission sale gsk spend gsk use contract manufacturer number million date expect spend country supply certain product local million remediation exist site market case specialist process design implement remediation technology integral project work government agency product supply chain work local community use good technology prevent adverse event ensure reliability available clean land allow return product supply ensure company use community parkland manage ehs risk impact responsibly conformance gsk requirement legislation site land contaminate assess programme ehs audit past storage disposal practice include conduct ehs global audit team poor containment accidental release commercial disposal site global standard audits cover general management ehs system place cover phase control key risk impact area waste management design prevent future improvement highlight contract incident contaminate land manufacturer progress monitor key contract manufacturerssupplier assess environmental performance gsk heritage company realise benefit ozone depletion chlorofluorocarbon cfc set target improve environmental elimination meter dose inhaler mdi performance improvement project start common way asthmatic receive continue future chart medication mdi use illustrate improvement achieve propellant cfc ozone deplete air emission voc wastewater discharge cod global warming gas hazardous waste dispose year lead gsk baseline currently gsk extensive plan contain milestone eliminate cfc recent performance datum eh mdi progress excellent cent target available website action complete time transition begin gsk manufactured example environmental million noncfc mdi launch performance improvement noncfc mdi cfcfree ventolin couple offer wide choice dry powder device confident ability transition away cfcs believe montreal target protocol essentialuse exemption allow manufacture cfcs salbutamolalbuterol active ingredient ventolin mdi market salbutamolalbuterol mdi contain cfc long necessary year contaminate land figure normalise sale currently study actively clean key vocvolatile organic compound emit air site class contaminate land codchemical oxygen demand wastewater remediate number hwdhazardous waste dispose manufacturing site preparation case study innovative approach deliver excellent safety record construction gsk new horlick plant india gsk recently complete build new new approach major greenfield factory sonepat north india meet site construction project india historically grow demand country horlick project type involve high level gsk popular nutritional drink attention health safety formal safety train common result project involve construction initiative accomplish partnership personnel total million hour construction management subcontract work year peak company sonepat return good worker site time worker losttime accident figure see project site day ensure gsk legacy company benefit change workforce aware safety health safety planning demonstrate health issue significant challenge immediately improve course project million hour health safety give priority work losttime injury illnesse construction plan appropriate lasting benefit project future programme place site application lesson learn create include provide hour site health facility safety culture injury illness treat early worker need leave site treatment project ehs initiative award induction train new worker emphasise safety sponsor chief executive officer inspector monitor highrisk area site select panel judge represent weekly talk safety topic special training academia government ngo gsk board programme scaffolder hold director high standard honesty integrity vital success businessperformance integrityis principle aim live work gsk business ethic integrity glaxosmithkline code conduct lay principle company value employee apply daily work responsibility employee implement code sustain trust confidence gsk stakeholder corporateethicsand compliance framework include risk oversight gsk commit operate law compliance council sector high ethical standard healthcare business unit risk management compliance industry highly regulate discovery board risk oversight compliance council development manufacturing marketing board assist identification mitigation medicine complex process aim risk provide guidance risk management build adherence high standard everyday initiative corporate business unit level management process activity risk oversight compliance council report formal company police procedure set audit committee gsk board expect standard conduct effective chief executive officer report communication training standard corporate executive team report line follow regular monitoring periodic review audit committee provide mechanism work output critical lawyer bypass executive management irregularity compliance officer closely involve establish identify communicating standard gsk emphasise personal responsibility employee line gsk risk management compliance framework manager ensure employee observe principle everyday work support corporate social audit committee gsk board responsibility committee undertake ethic training computer base session interactive discussion ceo corporate ethic compliance function gsk responsible support development cet businessandfunctionhead implementation practice facilitate employee compliance law company risk oversight compliance council rocc policy specialist compliance officer support main operation pharmaceuticals consumer healthcare manufacturing business unit functional risk management compliance board internal control framework integrate ethic business functional group compliance daytoday management group framework supports line potential risk riskgenerate activity function management identification mitigation significant risk potential compliance failure confidential tollfree line compliance officer available employee report concern gsk policy gsk code conduct gsk policy available internal website guide business conduct publish internal website support employee understand implementation standard guide summarise policy explain company expectation business ethic good business conduct notification system confidential integrity help line compliance officer available employee report concern feel deal adequately normal management system help line available employee reach half total gsk workforce employee advantage email access compliance officer report concern confidential post office box maintain corporate ethic compliance help line primarily consultation employee ask question result number caller inquiry receive compliance officer tends increase response training change issuance new policy activity level reflect great awareness policy legal requirement trend unacceptable practice response level indicate existence system purpose understand case study senior manager gsk expect lead example work line code conduct gsk policy support staff ensure understand fall people supervision receive responsibility gsk introduce copy access gsk code certification process world conduct gsk policy understand manager vicepresident level responsibility certification require manager sign manager vice statement confirm awareness president level complete certification obligation implement company code believe process support conduct policy include confirm dissemination awareness gsk ethical standard code conduct fthey know personally oblige comply importance thousand gsk employee applicable law regulation gsk course daily activity corporate local policy procedure work line law gsk policy fthey accept responsibility place appropriate measure ensure people supervision aware obligation management csr contribute improve people live responsible corporate citizen integral establish business practice corporate social responsibility csr believe stakeholder discussion activity include cover report require specialist knowledge well manage appropriate function undertake expertise organisation central team representative discuss issue directly department believe effective express interest concern approach manage issue central coordination mean broad remain integrated everyday issue bring attention operation business crossfunctional team facilitate policy development implementation gsk process place identify evaluate communication crossfunctional team manage significant business risk establish begin ensure include reputational corporate responsibility comprehensive coordinate approach issue risk management process accord team representative key turnbull guidance formal risk assessment business area ensure policy place update year risk oversight mechanism exist implementation compliance council coordinate monitor representative contribute internal control risk management activity report progress report ensure effective management significant risk way example conference presentation website year csr committee non executive board member give advice year crossfunctional team develop report activity specific input indicator support report key issue approach community investment determine indicator aim strike environment health safety human resource balance desire stakeholder policy include diversity human right issue great transparency operation reality cost run business crossfunctional management gsk board csr committee csr activity ceo cet member csr coordination global government reporting affair public policy disease medicine ethical issue care business develop support community develop develop ethic human right investment world world environment employee web reference corporate website find wwwgskcom website cite report wwwgskcomsersercsrpdf wwwgskcomcommunity wwwpolioeradicationorg wwwprojecthopeorg wwwgskcompressarchivepresshtm wwwpqmdorg wwwtogetherrxcom wwwgskcompressarchivepresshtm wwwgskcomaboutdevelopingworldhtm wwwicacuktemplatestextaspp wwwniaidnihgovfactsheetshvtnhtm wwwcorporatecitizenshipcoukcommunitylbgasp wwwwhointinfprenprhtml wwwrdsonlineorguknewshtml wwwgskcomaboutnfppricingguidehtm wwwaaalacorg wwwgskcompressarchivepresshtm httpsciencegskcomaboutanimalresearchhtm wwwgskcomcommunityabouthtm wwwphrmaorgpublicationsquickfactscfm wwwgskcomfilariasisindexhtm wwwunorgoverviewrightshtml wwwgskcompositiveactionindexhtm wwwiloorgpublicenglishstandardsdecldeclarationtextindexhtm wwwgskcompressarchivepresshtm wwwoecdorgpdfmmpdf wwwgskfrgskfondmphtml wwwgskcomserserehspdf wwwgskcommalariaindexhtm corporatesocialresponsibility committee donald mchenry sir christopher hogg nonexecutive director glaxosmithkline sir christopher nonexecutive chairman chairman corporate social responsibility glaxosmithkline nonexecutive chairman committee mchenryis distinguished reuters group plc member supervisory professor practice diplomacy school board air liquide chairman foreign service georgetown university royal national theatre presidentof ircgroup llc michle barzach lucy shapiro nonexecutive director glaxosmithkline nonexecutive director glaxosmithkline barzach member international shapiro ludwig professor cancer research cooperation high council chairman board department developmental biology equilibre population director director beckman centre molecular board project hope international consultant genetic medicine stanford university school health strategy french minister medicine health family question view share contact design consultancy salterbaxter csrcontactgskcomor write product name publication indicate italic csr trademarks glaxosmithkline plc subsidiary associate company global public policy glaxosmithkline print ives westerham press paper great west road production document pulp harvest fromsustainable brentford forest sawmill residue forest thinning elemental middlesex chlorinefree ukwwwgskcom